Business
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026)OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record dateOSAH to focus primarily on the re-establishment of USDA conditional approval and commercialization of immunotherapy OST-HER2 for
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026)","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"OSAH to focus primarily on the re-establishment of USDA conditional approval and commercialization of immunotherapy OST-HER2 for canine osteosarcoma and other HER2 positive cancers in animals","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"OST-HER2 featured in 2025 2x Emmy-nominated and Anthem Award-winning documentary 'Shelter Me: Cancer Pioneers' streaming on PBS","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"OSTX reiterates release date of January 15, 2026 for biomarker data from Phase 2b OST-HER2 trial in human pulmonary metastatic osteosarcoma that will be used to support upcoming Biologics License Application submission with US FDA","length":230,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":928,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - January 14, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that its wholly-owned subsidiary OS Animal Health Corp (OSAH) has filed a Form S-1 with the Securities Exchange Commission (SEC) in preparation for an Initial Public Offering (IPO). OSAH intends to list on either the NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026). OS Therapies shareholders are expected to receive one (1) share of OSAH for every ten (10) shares of OS Therapies owned as of the to-be-determined 1H/2026 record date.","length":713,"tagName":"p"},{"type":"text","content":"A 2023 research publication in Communications Biology provided evidence of key similarities in the molecular makeup and clinical behavior of human and canine osteosarcoma. Many of the genes that are upregulated in canine patients with better clinical out...